Clinical trial · Interventional
Acupuncture for Peripheral Neuropathy
A Study of Acupuncture for Bortezomib or Thalidomide -Induced Peripheral Neuropathy in Patients With Multiple Myeloma or Lymphoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): poor recruitment and expiry of funding
Summary
Brief summary (as posted)
A significant proportion (up to 60%) of myeloma patients treated with Bortezomib or thalidomide or both develop significant peripheral neuropathy (PN). Standard of care for this complication include drugs like gabapentin or pregabalin, which relieve symptoms only partially. PN of grade II or above mandates reduction in dose or frequency of Bortezomib or thalidomide, which may compromise treatment outcome. This clinical study explores whether, by intervening early in its course using acupuncture, progression of PN can be reversed, stabilized or retarded thereby allowing continuation of treatment on schedule.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Peripheral Neuropathy Grade 2 or Greater | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| acupuncture | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- acupuncture treatment
- interventionNames
- Procedure: acupuncture
Primary outcomes (1)
- measure
- Improvement in peripheral neuropathy
- timeFrame
- within the 5 weeks of acupuncture treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 21 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age \> 21 years and have a diagnosis of a plasma cell dyscrasia or lymphoma. 2. Patients must have neuropathy greater or equal to 2 according to CTCAE v 3.0 scale in spite of adequate duration (at least 3 weeks) of previous treatment with Gabapentin or Pregabalin or are unable to tolerate these drugs. Patients receiving any of these drugs must remain on the same medications throughout the study period; however, minor adjustments in dosage are allowed. 3\. The patient's current or previous treatment must include bortezomib or thalidomide 4\. ECOG Performance Status of 0, 1, or 2 Exclusion Criteria: 1. Local infection at or near the acupuncture site. (Although acupuncture is a minimally invasive procedure, patients will be excluded if there is an indication of active infection.) 2. Thrombocytopenia (platelet counts \< 50x 109/L) on the day of acupuncture session 3. Deformities that could interfere with accurate acupuncture point location or out of energy pathway as defined by traditional acupuncture theory. 4. Concurrent use of anticoagulation agents. 5. Known coagulopathy and taking heparin (including low molecular weight heparin) or warfarin at any dose. Patients on aspirin or non-steroidal anti-inflammatories are allowed to participate. 6. Persistent absolute neutrophil counts of \< 1 x 109/L 7. Active CNS disease. 8. Patients having a cardiac pacemaker. 9. Currently pregnant or lactating females. 10. Severe diabetic neuropathy or neuropathy related to HIV. 11. Previous acupuncture treatment for any indication within 30 days of enrollment.
References
Publications (0)
Data not yet available